Novo Nordisk Posts DKK 3.22 Billion Oral Wegovy Revenue, Opening An Early Lead Over Lilly’s Foundayo

Novo Nordisk has opened the first clear commercial lead in the oral obesity market, at least on the early numbers now available from the second quarter of 2026. Oral Wegovy recorded DKK 3.22 billion, or $496 million, in revenue, while Eli Lilly’s Foundayo posted $98 million in its first full quarter after April approval.

That gap matters because Lilly previously used stronger efficacy in injectables to overtake Novo in the GLP-1 market. In oral obesity, the source article describes the dynamic differently: Novo entered with an extension of an already established Wegovy franchise, giving it immediate physician familiarity, patient awareness, and semaglutide recognition that Lilly does not yet have for Foundayo.

The commercial picture

Sadaf Javed, manager of forecasting at DelveInsight, said the early difference reflects more than timing. Her view is that Novo benefited from extending the Wegovy brand into a pill rather than building a new obesity brand from scratch. Sara Reci, managing pharma analyst at GlobalData, made the same point in different terms, calling Novo’s advantage a structural first-mover benefit tied to the semaglutide franchise’s brand equity.

That commercial setup matters in obesity because patient and prescriber education can be expensive and slow. Reci said the name “Wegovy pill” is immediately legible to people who already know the injectable, reducing the amount of commercial explanation needed compared with a new brand.

The source also frames efficacy as part of Novo’s lead. Oral Wegovy showed around 16.6% weight loss at 72 weeks, versus 11.2% for Foundayo at the same time point. There has been no direct head-to-head comparison, but Reci still gave the efficacy edge to Novo’s product. Her read is that the oral market has, for now, removed the same lever Lilly used in injectables, where tirzepatide’s stronger profile helped the company dislodge Novo quickly.

Where Lilly can press

Lilly’s most immediate advantage is convenience. Javed said Foundayo has a simpler administration schedule than oral Wegovy. Novo’s pill needs to be taken with water and cannot be followed by any additional food or drink for at least 30 minutes, while Foundayo does not carry those restrictions.

That difference could become more important as the oral category matures and patients gain more options. Javed said convenience could influence both treatment initiation and switching, making dosing simplicity a more meaningful differentiator later than it appears in the first wave of launch sales.

Lilly also has commercial tools beyond the product label. Javed pointed to the company’s established Zepbound and Mounjaro commercial ecosystem, including its direct-to-consumer network, physician reach, existing patient awareness, and experienced sales and marketing infrastructure. The implication is that Lilly does not need to build obesity-market capabilities from zero even if Foundayo itself is a newer brand.

Srikripa Devarakonda, vice president of Biotechnology Equity Research at Truist Securities, argued Lilly may have an especially strong opportunity outside the U.S. Her view is that Foundayo is a bigger ex-U.S. play because overseas markets are more price-sensitive. She said Lilly could compete more effectively on price there because Foundayo is a small-molecule drug, which she described as easier and less costly to manufacture than oral Wegovy, a peptide.

In the U.S., Devarakonda’s view is different. Rather than cutting prices aggressively, she said Lilly’s better move would be marketing and access expansion.

What Novo has to defend

For Novo, the signal from this early lead is favorable but not self-executing. Javed said the company’s challenge is no longer simply to capture the oral GLP-1 market, but to turn early momentum into a durable position. She identified supply reliability, competitive pricing, and payer coverage as core requirements for doing that at scale.

She also argued Novo needs to sharpen the pill’s value proposition, especially against Lilly’s simpler administration profile. That point goes beyond launch sales: if patients begin to weigh convenience more heavily once multiple oral options are available, early brand familiarity may not be enough on its own.

The broader strategic lesson from the source is that oral obesity may not replay the injectable market exactly, but it probably will not stay frozen in its current configuration either. When Lilly entered GLP-1 with Mounjaro in 2022, it was almost five years behind Novo, which won approval for Ozempic in late 2017. Within three years, Lilly had overtaken Novo as the market frontrunner, helped by tirzepatide’s potentially greater weight reduction and sugar control effects.

Javed said something similar could happen again as obesity treatment moves beyond the current oral stage and toward next-generation therapies. Her conclusion was that Novo’s early oral GLP-1 lead is meaningful, but unlikely to be permanent. The current quarter shows that brand extension and stronger reported weight-loss data can secure an early lead; the longer contest may depend more on how each company balances efficacy, convenience, access, value, and the next products that follow these first pills.